IL-17C as a Driver of Inflammation in Psoriasis

By afschroeder • September 24, 2025

Han G, Armstrong A, Krueger JG, Jacobson A. IL-17C as a Driver of Inflammation in Psoriasis. Adv Ther. 2025 Sep 23. doi: 10.1007/s12325-025-03363-9. Epub ahead of print. PMID: 40986185.

Tags: Amplification+, biologic therapy, brodalumab, Dermatology, IL-17 family, IL-17 receptor A, Publications, Skin inflammation

Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

Augustin M, Armstrong A, Issa NT, Petersen AS, von Eyben R, Festini T, Torres T. Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy[...]

Efficacy and Safety of Tralokinumab Across Racial Subgroups in Adults with Moderate-to-Severe Atopic Dermatitis: Post Hoc Analysis of Phase III Trials

Mayo T, Silverberg JI, Armstrong A, Guttman-Yassky E, Blauvelt A, Esdaile B, Kabashima K, Gooderham M, Kircik L, Schneider S, Bennike N, von Eyben R,[...]

Bidirectional risk between autoimmune blistering diseases and posttraumatic stress disorder

Kasperkiewicz M, Ludwig RJ, Curman P. Bidirectional risk between autoimmune blistering diseases and posttraumatic stress disorder. J Eur Acad Dermatol Venereol. 2025 Oct 17. doi:[...]